Biospecifics Technologies Corp (NASDAQ:BSTC) Institutional Investor Positioning

September 8, 2018 - By Carolyn Hewitt

Sentiment for Biospecifics Technologies Corp (NASDAQ:BSTC)

Biospecifics Technologies Corp (NASDAQ:BSTC) institutional sentiment decreased to 0.77 in Q1 2018. Its down -0.45, from 1.22 in 2017Q4. The ratio fall, as 33 hedge funds increased and started new stock positions, while 43 decreased and sold equity positions in Biospecifics Technologies Corp. The hedge funds in our partner’s database reported: 3.50 million shares, down from 3.63 million shares in 2017Q4. Also, the number of hedge funds holding Biospecifics Technologies Corp in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 14 Reduced: 29 Increased: 21 New Position: 12.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $422.96 million. The firm offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 31.01 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

The stock increased 6.33% or $3.45 during the last trading session, reaching $57.98. About 78,485 shares traded or 152.15% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has declined 16.75% since September 8, 2017 and is downtrending. It has underperformed by 29.32% the S&P500.

Analysts await BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report earnings on November, 9. They expect $0.55 EPS, up 48.65 % or $0.18 from last year’s $0.37 per share. BSTC’s profit will be $4.01M for 26.35 P/E if the $0.55 EPS becomes a reality. After $0.59 actual EPS reported by BioSpecifics Technologies Corp. for the previous quarter, Wall Street now forecasts -6.78 % negative EPS growth.

Jw Asset Management Llc holds 3.22% of its portfolio in BioSpecifics Technologies Corp. for 73,649 shares. Elk Creek Partners Llc owns 165,085 shares or 0.43% of their US portfolio. Moreover, Rice Hall James & Associates Llc has 0.28% invested in the company for 161,754 shares. The Connecticut-based Thomson Horstmann & Bryant Inc has invested 0.27% in the stock. Secor Capital Advisors Lp, a New York-based fund reported 16,976 shares.

Since January 1, 0001, it had 0 insider purchases, and 6 selling transactions for $4.60 million activity.

Another recent and important BioSpecifics Technologies Corp. (NASDAQ:BSTC) news was published by Nasdaq.com which published an article titled: “Market Trends Toward New Normal in Addus HomeCare, Sandstorm Gold, BioSpecifics Technologies, Itau Unibanco …” on August 21, 2018.

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.